Table 4.
Demographic characteristic of HCC patients with BCLC 0 and A stage
| Variables | Hepatectomy (n = 126) | LT (n = 53) | P-value |
|---|---|---|---|
| Age (years) | 49.9 ± 11.1 | 49.9 ± 11.2 | 0.892 |
| Gender, M/F | 121 (96.0%)/5 (4.0%) | 50 (98.4%)/3 (1.6%) | 0.671 |
| AFP (ng/ml), ≤ 400/ > 400 | 82 (65.1%)/34 (34.9%) | 42 (79.2%)/11 (20.8%) | 0.243 |
| HBV-DNA, ± | 88 (69.8%)/38 (30.1%) | 26 (49.1%)/27 (50.9%) | 0.008 |
| Prothrombin time (s) | 13.6 ± 1.2 | 14.6 ± 3.2 | 0.001 |
| FIB-4 | 2.5 ± 1.9 | 2.7 ± 1.5 | 0.464 |
| Tumor size (cm), < 5/ ≥ 5 | 76 (60.3%)/50 (49.7%) | 28 (52.8%)/25 (47.2%) | 0.354 |
| Tumor nodule number, Single / Multiple (≥ 2) | 122 (96.8%)/4 (3.2%) | 50 (94.4%)/3 (5.6%) | 0.433 |
| MVI, ± | 14 (11.1%)/112 (88.9%) | 16 (30.2%)/37 (69.8%) | 0.002 |
| Differentiation gradea, I–II/III–IV | 118 (93.7%)/8 (6.3%) | 47 (88.7%)/6 (11.3%) | 0.258 |
| BCLC stage, 0/A | 20 (15.9%)/106 (84.1%) | 12 (22.6%)/41 (77.4%) | 0.281 |
HCC hepatocellular carcinoma, BCLC Barcelona Clinic Liver Cancer, LT liver transplantation, AFP alpha-fetoprotein, MVI microvascular invasion, HCC hepatocellular carcinoma
aEdmondson-Steiner grade